1-5 of 5
Himachandana Atluri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Himachandana Atluri, Jillian Mullin, Koichi Takahashi, Sanam Loghavi, Abhishek Maiti, Koji Sasaki, Naval Daver, Yesid Alvarado Valero, Naveen Pemmaraju, Gautam Borthakur, Danielle E. Hammond, Kelly S. Chien, Alessandra Ferrajoli, Nicholas J. Short, Hussein A Abbas, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Rebecca S.S. Tidwell, Xuemei Wang, Marina Y. Konopleva, Guillermo Garcia-Manero, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood
Blood (2023) 142 (Supplement 1): 968.
https://doi.org/10.1182/blood-2023-182944
Published: 2023
Journal Articles

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Himachandana Atluri, Jeremy DiGennaro, Keyur P. Patel, Mark Routbort, Betul Oran, Ghayas C. Issa, Nicholas J. Short, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Uday R. Popat, Richard E. Champlin, Elizabeth J. Shpall, Sherry Pierce, Rashmi Kanagal-Shamanna, Chi Young Ok, Guilin Tang, Sa A. Wang, Raja Luthra, Audrey Lasry, Bettina Nadorp, Antonia Chroni, Ann-Kathrin Eisfeld, Iannis Aifantis, Najla H Al Ali, David A Sallman, Jeffrey Lancet, Onyee Chan, Eric Padron, Zhuoer Xie, L. Jeffrey Medeiros, Courtney D. DiNardo, Rami S. Komrokji, Sanam Loghavi
Journal: Blood
Blood (2023) 142 (Supplement 1): 959.
https://doi.org/10.1182/blood-2023-188319
Published: 2023
Journal Articles

A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA

Aram Bidikian, Sreyashi Basu, He Zhong, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa
Journal: Blood
Blood (2022) 140 (Supplement 1): 6739–6741.
https://doi.org/10.1182/blood-2022-165509
Published: 2022
Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Himachandana Atluri, Abhishek Maiti, Koji Sasaki, Naval Daver, Yesid Alvarado, Md Feroz Hossain, Xuemei Wang, Naveen Pemmaraju, Koichi Takahashi, Gautam Borthakur, Alessandra Ferrajoli, Nicholas Short, Hussein A Abbas, Farhad Ravandi, Elias Jabbour, Michael Andreeff, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 6170–6172.
https://doi.org/10.1182/blood-2022-164986
Published: 2022
Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Mark A. Schroeder, Jaebok Choi, Himachandana Atluri, Jordan Atkins, Melinda Harding, Jeremy Eisele, Feng Gao, Ramzi Abboud, Camille Abboud, Sr., Amanda F. Cashen, Matthew Christopher, Todd A. Fehniger, Francesca Ferraro, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E Stockerl-Goldstein, Geoffrey L. Uy, Ravi Vij, Matthew J Walter, Peter Westervelt, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 1875–1876.
https://doi.org/10.1182/blood-2022-157214
Published: 2022